Elite Pharmaceuticals, Inc. Announces Fiscal Year 2013

New Post Public Reply Private Reply Replies (2) Message Board

Nov 13, 2012 at 1:45 PM

Elite Pharmaceuticals, Inc. Announces Fiscal Year 2013 Second Quarter Investor Conference Call on Thursday, November 15, 2012
GlobeNewswire

NORTHVALE, N.J., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today the Company will host a conference call on Thursday, November 15, 2012 at 10:00 AM EST to review the fiscal second quarter results of operations and provide an update on recent business developments. Company executives will also conduct a question and answer session following their remarks.

To access the conference call: Domestic callers: (800) 346-7359 International callers: (973) 528-0008 Conference Entry Code: 98840 A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until November 29, 2012 by dialing: Domestic callers: (800) 332-6854 International callers: (973) 528-0005 Conference entry code: 98840
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has three commercial products being sold through a partner, one product produced for partners under contract manufacturing agreements, two additional products approved and pending launch, and three products under review, pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
The Elite Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8737
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements These risks and other factors, including, without limitation, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Radiation Oncologist Dr. Pennock Honored: A Closer Look

An Honor from The Inner Circle Sometimes, in a field stuffed with brilliant minds, a beacon stands out. That's Dr. Michael M. Pennock for you—a man who doesn’t just treat cancer patients but transforms their journeys with precision and empathy. Recognized as a Pinnacle Lifetime Member by The Inner Circle, Pennock’s dedication in the field of radiation oncology is...

Infection Control Market Set for Explosive Growth by 2031

Untangling the Surge in Infection Control Demand Lately, it's like every healthcare joint worldwide is scrambling for better infection control. We're talking about a market poised to jump from a whopping USD 58.5 billion in 2026 to USD 80.2 billion by 2031—a tidy 37% uptick. That change, brewing at a 6.5% CAGR, speaks volumes about where the industry's heading. What's...

CashNetUSA Faces Class Action Over Exploitative Rates

High-Risk Lending Meets Military Protections Ever seen a seemingly legal scheme that just leaves a sour taste? That's the vibe with CashNetUSA right now. They've landed in the hot seat over allegedly sky-high interest rates served up to folks who put on a uniform. We're talking about a proposed nationwide class action lawsuit accusing the lender of giving active-duty...

Danobatgroup's New HQ in Shanghai Marks Strategic Shift

Shanghai Beckons: A Game Changer for Danobatgroup One crisp morning in Shanghai marks a turning point for Danobatgroup. The Spanish heavy-hitter in machine tools has pinpointed the Shanghai Xinzhuang Industry Park in Minhang District for its Asia-Pacific headquarters. It ain't just another blip on the radar—this one's a calculated leap. Location, Location, Location...

FluxCap Launches: Empowering Lawyers with Dynamic Tech

A Fresh Force in Legal Tech: FluxCap Debuts Alright, strap in because the legal world just got itself a new team in the majors. FluxCap is breaking out into the open, promising to shake up how big, gnarly cases get tackled. These aren't just any cases; we're talking the kind that keep antitrust knuckles white and palms sweaty. It's like watching seasoned racecar drivers...

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Sony's LYTIA 720 Image Sensor: A Game Changer?

Unpacking Sony's Latest Sensor: LYTIA 720 Tell me, when was the last time a tech drop made you shake your head in awe? Sony just pulled one of those moves with their latest toy, the LYTIA 720. We're talking a 50-effective megapixel CMOS image sensor crafted for mobile warriors, and it packs a punch that should have the competition looking over their shoulder. Dazzling...

Civitas Boosts Orlando Luxury Hotel with $386M Loan

Orlando Sets the Stage for Luxury Expansion Well, it seems Orlando's hospitality scene is about to get a significant bump. Civitas Capital Group just tossed a cool $386 million into the pot for the construction of a 700-key luxury hotel on the infamous International Drive. We're not talking about just another hotel here; this one's a real beast, a future InterContinental...